Stock Price Quote

PANACEA BIOTEC LTD.

NSE : PANACEABIOBSE : 531349ISIN CODE : INE922B01023Industry : Pharmaceuticals & DrugsHouse : Soshil Kumar Jain
BSE350.00-7.35 (-2.06 %)
PREV CLOSE ( ) 357.35
OPEN PRICE ( ) 358.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1833
TODAY'S LOW / HIGH ( )350.00 358.00
52 WK LOW / HIGH ( )282.15 581
NSE351.35-5.8 (-1.62 %)
PREV CLOSE( ) 357.15
OPEN PRICE ( ) 358.20
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 17438
TODAY'S LOW / HIGH( ) 350.10 358.35
52 WK LOW / HIGH ( )281.1 581.9
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1984
Management Info
Rajesh Jain - Chairman Rajesh Jain - Managing Director
Registered Office

Address Ambala - Chandigarh Highway,,,
Lalru,
Punjab-140501

Phone 01762- 505900

Email companysec@panaceabiotec.com

Website www.panaceabiotec.com

Registrars Details
Skyline Financial Services Pvt Ltd
D-153/A, 1st Floor,Okhla Industrial Area,Phase - I,New Delhi
Listing : BSE, NSE

NEWS

12Nov Panacea Biotec gets Award notification
Panacea Biotec has received an Award notification from Pan American Heal..
12Nov Panacea Biotec gains on getting Award
Panacea Biotec is currently trading at Rs 399.90, up by 3.50 points or 0..
09Oct Panacea Biotec gets LoA worth Rs 127.2
Panacea Biotec has received a Letter of Acceptance (LoA) worth Rs 127.2..
03Oct Panacea Biotec gets LoA worth Rs 315 c
Panacea Biotec has received a letter of award (LoA) worth around $35.65..
03Oct Panacea Biotec informs about receipt
In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosur..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit-156.4-152.3
Gross Profit -209.3 -260.6
Operating Profit -100.996.8999999999996
Net Sales 908.13098.5

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE)
peergroup  1445.00 (7.57%)
M.Cap ( in Cr)808.52
Fredun Pharma (BSE)
peergroup  1743.40 (5.00%)
M.Cap ( in Cr)788.52
Acutaas Chemicals (BSE)
peergroup  1681.00 (3.09%)
M.Cap ( in Cr)13828.03
Alkem Laboratories (BSE)
peergroup  5661.85 (0.81%)
M.Cap ( in Cr)67081.35
Procter&Gamble Healt (BSE)
peergroup  5703.25 (0.48%)
M.Cap ( in Cr)9397.74

Shareholding Pattern

PROMOTERS 72.48%
NON-INSTITUTION 24.66%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Panacea Biotec Ltd.

Panacea Biotec Ltd. was incorporated in the year 1984. Its today's share price is 350. Its current market capitalisation stands at Rs 2168.28 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3113.84 Cr and Total Income of Rs.3264.73 Cr. The company's management includes Venkatesh Sarvasiddhi, Rajender Pal Singh, Rajesh Jain, Mukul Gupta, Krishan Kumar Jalan, Ambika Sharma, Sanjay Trehan, Harshet Jain, Ankesh Jain, Sandeep Jain, Rajesh Jain, Rajesh Jain, Vinod Goel.

It is listed on the BSE with a BSE Code of 531349 , NSE with an NSE Symbol of PANACEABIO and ISIN of INE922B01023. It's Registered office is at Ambala - Chandigarh Highway,,Lalru-140501, Punjab. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are SR Batliboi & Co LLP, Suresh Surana & Associates LLP, Walker Chandiok & Co, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.